Related Experiment Video

Updated: May 3, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Approval of New Agents after Phase II Trials

Bruce Chabner1

  • 1From the Massachusetts General Hospital Cancer Center, Boston, MA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|January 24, 2014
PubMed

Insights

Cancer drug approvals are shifting towards earlier evidence, especially for targeted therapies in non-responsive patients. Accelerated approval is possible with strong early data and validated biomarkers.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Pharmacology

Background:

  • Cancer drug development traditionally relies on Phase III trials for efficacy proof.
  • Advancements in cancer biology and targeted therapies enable earlier patient selection.
  • Conventional therapies often show limited efficacy in specific patient populations.

Purpose of the Study:

  • To discuss the evolving landscape of cancer drug approval pathways.
  • To explore the potential for accelerated approval based on early trial data.
  • To analyze the benefits and drawbacks of rapid drug approval scenarios.

Main Methods:

  • Review of current cancer drug approval standards.
  • Analysis of early-phase clinical trial data (Phase I expansion cohorts).
  • Consideration of biomarker validation and patient selection strategies.

Main Results:

  • Early trials, particularly Phase I expansion cohorts, can provide strong evidence of response rates.
  • Accelerated approval may be feasible for targeted agents with high response rates in specific populations.
  • Biomarker availability and drug safety profile are critical for accelerated approval.

Conclusions:

  • The traditional reliance on Phase III trials for cancer drug approval is being challenged.
  • Accelerated approval pathways offer faster access to novel targeted therapies.
  • Careful consideration of advantages and disadvantages is necessary for rapid approval scenarios.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.8K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.9K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.7K